Population pharmacokinetic analysis and dosing regimen optimization of aprotinin in neonates and young infants undergoing cardiopulmonary bypass

Journal of Clinical Pharmacology

Volumn 51, Issue 8, 2011, Pages 1163-1176

  Tae, You Me ^a   Kwak, Jae Gun ^b   Kim, Bo Hyung ^c   Jang, In Jin ^c   Kim, Woong Han ^d  

^a Pohang University of Science and Technology (POSTECH)   (South Korea)

^b Sejong General Hospital   (South Korea)

^c Seoul National University Hospital   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

aprotinin; cardiopulmonary bypass; dosing; neonates; population pharmacokinetics

Indexed keywords

APROTININ;

AORTA ARCH INTERRUPTION; AORTA COARCTATION; ARTICLE; ATRIOVENTRICULAR SEPTAL DEFECT; BLOOD SAMPLING; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTINUOUS INFUSION; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; GREAT VESSELS TRANSPOSITION; HEART ATRIUM SEPTUM DEFECT; HEART RIGHT VENTRICLE DOUBLE OUTLET; HEART VENTRICLE SEPTUM DEFECT; HUMAN; INFANT; LUNG VEIN DRAINAGE ANOMALY; MALE; MONTE CARLO METHOD; MORTALITY; NEWBORN; OPEN HEART SURGERY; OPTIMAL DRUG DOSE; PATENT DUCTUS ARTERIOSUS; SIMULATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIFIBRINOLYTIC AGENTS; APROTININ; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; CARDIOVASCULAR ABNORMALITIES; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HALF-LIFE; HUMANS; INFANT; INFANT, NEWBORN; KALLIKREINS; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; MONTE CARLO METHOD; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; SERINE PROTEINASE INHIBITORS;

EID: 79960717077     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010379411     Document Type: Article

References (30)

1. Hardy JF, Desroches J. Natural and synthetic antifibrinolytics in cardiac surgery. Can J Anaesth. 1992 ; 39: 353-365
2. Hunt BS, Yacoub M. Aprotinin and cardiac surgery. BMJ. 1991 ; 303: 660-661
3. Peters DC, Noble S. Aprotinin: an update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery. Drugs. 1999 ; 57: 233-260 (Pubitemid 29116517)
4. Royston D. High-dose aprotinin therapy: a review of the first five years' experience. J Cardiothorac Vasc Anesth. 1992 ; 6: 76-100
5. Buylaert WA, Herregods LL, Mortier EP, Bogaert MG. Cardiopulmonary bypass and the pharmacokinetics of drugs. An update. Clin Pharmacokinet. 1989 ; 17: 10-26 (Pubitemid 19187877)
6. Mets B. The pharmacokinetics of anesthetic drugs and adjuvants during cardiopulmonary bypass. Acta Anaesthesiol Scand. 2000 ; 44: 261-273 (Pubitemid 30131360)
7. Williams GD, Bratton SL, Ramamoorthy C. Factors associated with blood loss and blood product transfusions: a multivariate analysis in children after open-heart surgery. Anesth Analg. 1999 ; 89: 57-64 (Pubitemid 29293309)
8. D'Errico CC, Munro HM, Bove EL. Pro: the routine use of aprotinin during pediatric cardiac surgery is a benefit. J Cardiothorac Vasc Anesth. 1999 ; 13: 782-784 (Pubitemid 30007483)
9. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2006 ; 354: 353-365 (Pubitemid 43145060)
10. Karkouti K, Beattie WS, Dattilo KM, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion- risk cardiac surgery. Transfusion. 2006 ; 46: 327-338 (Pubitemid 43334084)
11. Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008 ; 358: 2319-2331 (Pubitemid 351749156)
12. Donato L, Mambrito B. The artificial heart: device and concept evolution. Technol Health Care. 1996 ; 4: 37-41 (Pubitemid 27062329)
13. Pea F, Pavan F, Furlanut M. Clinical relevance of pharmacokinetics and pharmacodynamics in cardiac critical care patients. Clin Pharmacokinet. 2008 ; 47: 449-462 (Pubitemid 351861957)
14. Oliver WC, Fass DN, Nuttall GA, et al. Variability of plasma aprotinin concentrations in pediatric patients undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2004 ; 127: 1670-1677 (Pubitemid 38725446)
15. Mossinger H, Dietrich W, Braun SL, et al. High-dose aprotinin reduces activation of hemostasis, allogeneic blood requirement, and duration of postoperative ventilation in pediatric cardiac surgery. Ann Thorac Surg. 2003 ; 75: 430-437 (Pubitemid 36184484)
16. Szekely A, Sapi E, Breuer T, et al. Aprotinin and renal dysfunction after pediatric cardiac surgery. Paediatr Anaesth. 2008 ; 18: 151-159
17. Breuer T, Martin K, Wilhelm M, et al. The blood sparing effect and the safety of aprotinin compared to tranexamic acid in paediatric cardiac surgery. Eur J Cardiothorac Surg. 2009 ; 35: 167-171
18. Twite MD, Hammer GB. The use of aprotinin in pediatric cardiac surgery: should we bid "good riddance" or are we throwing out the baby with the bath water?. Paediatr Anaesth. 2008 ; 18: 809-811
19. Backer CL, Kelle AM, Stewart RD, et al. Aprotinin is safe in pediatric patients undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2007 ; 134: 1421-1426
20. Williams GD, Ramamoorthy C, Pentcheva K, et al. A randomized, controlled trial of aprotinin in neonates undergoing open-heart surgery. Paediatr Anaesth. 2008 ; 18: 812-819
21. Guzzetta NA, Evans FM, Rosenberg ES, et al. The impact of aprotinin on postoperative renal dysfunction in neonates undergoing cardiopulmonary bypass: a retrospective analysis. Anesth Analg. 2009 ; 108: 448-455
22. Levy JH, Bailey JM, Salmenpera M. Pharmacokinetics of aprotinin in preoperative cardiac surgical patients. Anesthesiology. 1994 ; 80: 1013-1018 (Pubitemid 24150882)
23. O'Connor CJ, Brown DV, Avramov M, et al. The impact of renal dysfunction on aprotinin pharmacokinetics during cardiopulmonary bypass. Anesth Analg. 1999 ; 89: 1101-1107 (Pubitemid 29521923)
24. Bianchi C, Donadio C, Tramonti G, et al. 99mTc-aprotinin: a new tracer for kidney morphology and function. Eur J Nucl Med. 1984 ; 9: 257-260 (Pubitemid 14076182)
25. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008 ; 48: 303-332 (Pubitemid 351738156)
26. Hudson RJ, Thomson IR, Jassal R. Effects of cardiopulmonary bypass on sufentanil pharmacokinetics in patients undergoing coronary artery bypass surgery. Anesthesiology. 2004 ; 101: 862-871 (Pubitemid 39288035)
27. McCluskey SA, Cheung WK, Katznelson R, et al. The pharmacokinetic profile of recombinant human erythropoietin is unchanged in patients undergoing cardiac surgery. Eur J Clin Pharmacol. 2009 ; 65: 273-279
28. Elliott M. Minimizing the bypass circuit: a rational step in the development of paediatric perfusion. Perfusion. 1993 ; 8: 81-86 (Pubitemid 23055119)
29. Wachtfogel YT, Kucich U, Hack CE, et al. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg. 1993 ; 106: 1-9
30. Miller BE, Tosone SR, Tam VK, et al. Hematologic and economic impact of aprotinin in reoperative pediatric cardiac operations. Ann Thorac Surg. 1998 ; 66: 535-540 (Pubitemid 28410692)